TheranosticTrials.org

Clinical Trial · NCT05511714

Expanded Access [11C] Methionine PET Imaging

Overview

The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment. Primary Objective To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.

Sponsor

St. Jude Children's Research Hospital

Contacts

Barry L. Shulkin, MD, MBA (PRINCIPAL_INVESTIGATOR)

Barry L. Shulkin, MD, MBA (CONTACT)

referralinfo@stjude.org

888-226-4343

ClinicalTrials.gov

NCT05511714

Drug / Compound

Methionine

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • * All participants under the care of a SJCRH physician with known or suspected neoplastic disease of the CNS or head and neck are eligible for participation.
  • Patients of all genders and all ethnic groups under the care of a SJCRH physician.
  • Female participants of child-bearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
  • No limit on age.
  • Informed consent signed by participant, parent, or guardian according to the guidelines of the Institutional Review Board.

Exclusion

  • Inability or willingness of patient, parent, or guardian to consent.
  • * More than six L-\[11C\]methionine PET scans within the previous 12 months.